A single injection of the cannabinoid agonist R(+)WIN55,212-2 (WIN) is known to cause an increase of the mean duration of spontaneously occurring spike-and-wave discharges (SWDs) in rats of the WAG/Rij strain, a genetic model for absence epilepsy. The aim of the present study was to establish whether repeated activation of CB 1 receptors with WIN leads to tolerance in its effect on SWD parameters, spectral density, and behavior over time. Adult male WAG/Rij rats (n = 16) were treated with WIN (6 mg/kg) or vehicle (olive oil). Injections (s.c.) took place 3 times per week during 2 weeks. Electroencephalogram (EEG) recordings, each lasting 24 h, were made 3 times: immediately before the first injection (baseline), immediately after the first injection (acute treatment), and after 2 weeks of treatment (subchronic treatment). The recordings were analyzed regarding incidence, durations of SWDs, and hazard rates of the durations of SWDs, the latter to describe SWD stopping probabilities. Putative changes in the spectral content of the EEG before and after WIN during active and passive behaviors were additionally investigated. Spike-and-wave discharge incidence was not affected by the acute and subchronic treatments. The mean duration of the SWDs was significantly longer than controls in the acute WIN-treated animals [11.9-s standard error of the mean (SEM): 0.64 compared with 8.4-s SEM: 0.25] as well as in subchronically treated animals (11.5-s SEM: 1.00 compared with 8.4-s SEM: 0.25). Hazard rates were significantly lower for WIN-treated animals at SWD durations in the 5.04-20.16-s range on both occasions. No effects of WIN on the frequency spectrum of the ongoing EEG were found, neither acutely nor after repeated administration. Evidence for tolerance was not found. The results on the mean duration and hazard rates suggest that stimulating the endocannabinoid system affects the SWD stopping mechanism, resulting in more long SWDs. We speculate that this effect is likely to be a direct result of CB 1 receptor agonism and a subsequent decrease in the availability of gamma-aminobutyric acid (GABA) in the reticular thalamic nucleus, which further weakens, in WAG/Rij rats already disturbed, the stopping mechanism of the SWDs.
Introduction
The endogenous cannabinoid system is a neuromodulatory system that is involved in a wide variety of physiological functions [1] [2] [3] [4] . Its most common ligands are 2-AG (2-arachidonylglycerol) and AEA (arachidonylethanolamide; anandamide) [5] . The most common receptors are CB 1 and CB 2 [6] . The receptor (CB 1 R) is abundantly present throughout the central nervous system. It is present in high density throughout the cerebral cortex, the amygdala, and the hippocampus [7] . In the thalamus, the density of CB 1 receptors is markedly lower except in the reticular nucleus of the thalamus [8] , but their efficacy is much higher than in other parts of the brain because of tighter coupling with G protein-coupled receptors [9] .
Cannabinoids such as Δ 9 -tetrahydrocannabinol (THC) have been used recreatively as well as therapeutically for thousands of years, for a wide variety of ailments, including pain and depression [4] . Indeed, now that more light is being shed on the role of the endocannabinoid system, its vast therapeutic potential is becoming all the more clear. Since the endocannabinoid system is involved in controlling homeostasis of many systems, regulation of an overactive endocannabinoid system can have beneficial effects on a wide variety of conditions [10] , including the aforementioned pain [11, 12] and depression [4, 11] . It may also affect brain plasticity, learning and memory, neuronal Epilepsy & Behavior 102 (2020) 106722 ☆ This work is part of the research program Promotiebeurs voor Leraren with project number 023.001.118 financed by the Netherlands Organisation for Scientific Research (NWO). The funding organization had no involvement in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. development, appetite regulation and digestion, inflammation, and metabolism [13] [14] [15] [16] [17] .
The role of the endocannabinoid system in epilepsy is also of great interest. Results from animal models for brain injuries suggest a seizure protective role of the endocannabinoid system. CB 1 agonists attenuate several types of seizures [18] [19] [20] and retard the development of amygdala kindling [21, 22] . Additionally, the CB 1 agonist R(+)WIN55,212-2 (WIN) reduces status epilepticus and subsequent mortality in rats [23] . Moreover, cannabinoids decrease the power of the electroencephalogram (EEG) frequency spectrum between 7 and 27 Hz [24] .
Conversely, CB 1 antagonists, such as rimonabant, induce spontaneous convulsive seizures [25] [26] [27] or increase the occurrence of existing seizures in several in vitro [28] and in vivo [29] [30] [31] epilepsy or seizure models. There is also evidence in humans: partial seizures were observed in a patient treated with rimonabant for obesity, who had a history of idiopathic generalized epilepsy [32] .
Although the role of the endocannabinoid system in convulsive epilepsy is relatively clear, much less is known about its involvement in absence epilepsy. Absence epilepsy is one of the generalized forms of epilepsy. One of its forms, childhood absence epilepsy, is most common in young children, and the highly archetypical absence seizures are characterized by a reduction of awareness and responsiveness. The seizures characterizing absence epilepsy last from a few seconds up to half a minute. Sometimes, these seizures are too brief to be noticed without an EEG. In other cases, however, they cannot be overlooked because the person stops talking, is staring, or is lapsing into immobility [33] .
In the WAG/Rij rat model for absence epilepsy [34] , WIN caused a decrease of the incidence of spontaneously occurring spike-and-wave discharges (SWDs) in the first 3-h postinjection followed by a late increase in mean SWD duration [8] . Following treatment, CB 1 receptor messenger RNA (mRNA) and protein levels were reduced in the reticular thalamic nucleus (RTN), a key structure in the corticothalamocortical network involved in the propagation and maintenance of these seizures [35] . However, CB 1 receptors have been reported to be prone to plasticity [13, 16] , and tolerance to cannabinoids on behavior, cognitive functioning, and EEG has been reported in humans [36] [37] [38] as well as in rodents [39, 40] . However, in case of WIN, this is not entirely clear since repeated administration of this CB1 agonist did not lead to behavioral tolerance [41] . It is therefore of particular interest to investigate whether tolerance occurs regarding the effects of WIN on SWDs.
Given the increased mean SWD duration previously described in our acute study with WIN, it is relevant to study the distribution of SWD durations. Some drugs, such as vigabatrin and AY-9944, are known to alter the SWD stopping mechanism [42, 43] . Interestingly, the increase in mean duration was paralleled by a relatively small number of very long SWDs. Given that WIN is known to reduce convulsive status epilepticus in rats [23] whereas the CB 1 antagonist rimonabant induces status epilepticus-like activity in a neuronal cell culture model of acquired epilepsy [28] , it is not unlikely that manipulation of the CB 1 receptor may also result in alterations of the stopping mechanism of other types of seizures, such as absences, and consequently changes in the distribution of SWD durations.
In the present study, the effects of subchronic manipulation of the endogenous cannabinoid system of adult rats with the CB 1 agonist WIN were studied. Animals were exposed during two weeks to a dose of the drug that is known to affect SWD characteristics [8] . The aim was to establish whether repeated activation of CB1 receptors leads to changes in its effect on SWD parameters over time. Changes in the stopping mechanism might give rise to differences in the distribution of SWD durations rather than simply a net increase in mean duration. Therefore, hazard functions [42] were calculated. The spectral content of the compound on the ongoing EEG was analyzed as well, given an earlier report that the spectral density function was altered by cannabinoids. Finally, the physical activity of the rats was monitored and quantified throughout the 24-h recording period.
Methods

Animals
This study was performed in accordance with European Community guidelines for the use of experimental animals. Approval of the local committee for animal studies (RU-DEC 2012.111) was obtained.
Sixteen adult male WAG/Rij rats (age: 6 months) were used, born, and raised in the Department of Biological Psychology, Radboud University. Prior to the experiment, the rats were housed in pairs, in Makrolon (polycarbonate) type III laboratory cages containing wood shavings and cage enrichment, with food and water ad libitum and a 12-h-12-h light dark cycle with lights on at 8:00 pm in a temperature-controlled (20°C) environment. After surgery, the animals were housed individually under otherwise the same conditions.
Surgery
The animals were surgically provided with two tripolar EEG electrodes (Plastics One MS-332/2-A) under complete isoflurane anesthesia. An incision was made to expose the skull surface. The positions for the electrodes were established with aid of a stereotaxic frame (in mm from bregma; frontal cortex: + 2.0; − 3.5; hippocampus: [44, 45] . The reference electrode was placed over the parietal cortex (−6.0; −4.0), and the ground electrode was positioned above the cerebellum, on the contralateral side compared with the other electrodes. Holes for the electrodes and for two screws were drilled at the assigned areas. The electrodes were fixated to the skull with the screws and dental acrylic. Rimadyl was injected subcutaneously as an analgesic 24 and 48 h after surgery. The animals were allowed to recover for at least two weeks.
Drugs, injections, and treatment schedule
A baseline EEG of 24 h was recorded first. Subsequently, the first injection was given, immediately followed by a 24-h EEG recording. After 2 weeks, another 24-h EEG recording was made, again immediately following injection of the drug.
The cannabinoid agonist WIN (6 mg/kg in 3 ml/mg olive oil, s.c.) was injected three times a week during two weeks in 8 animals, early in the dark period. A control group of 8 animals was injected with the same volume of only the vehicle, olive oil. The dose was based on previous experiments [8] as 6 mg/kg was found to be the highest effective dose without significant animal discomfort.
EEG recordings
Each rat was individually placed in a transparent recording cage (25 × 30 × 35 cm), with food and water ad libitum. The animals were placed into the cages approximately 1 h before recording to allow them to habituate. They were connected via a swivel to the recording system, allowing them to move freely. For acute and subchronic treatments, the drug, or vehicle, was injected after this hour, and subsequently, the 24-h recording started immediately.
Electroencephalogram was recorded between 1 and 100 Hz at a sample rate of 512 Hz. A Windaq system (DATAQ Instruments, Akron, OH) was used to record and monitor the EEG, which was stored on hard disk for offline analysis. Recordings of two animals, one animal WIN-treated and one control, were made simultaneously. Movements were recorded throughout the EEG recording session with a passive infrared (PIR) motion sensor. One animal in the WIN group lost its electrode immediately after the baseline recording was made and was not included in the analysis.
SWD quantifying
For SWD quantifying, only data from the frontal cortex EEG channel were used. Spike-and-wave discharges of type1 [46, 47] were identified and marked automatically with spike-and-wave complex finder (Electronic Research Group, P. van den Broek, Radboud University, Nijmegen) and checked by a trained expert. The data were blinded for treatment.
Hazard rate
In order to examine the stopping mechanism of SWDs in WINtreated animals, hazard rate analyses [42] of SWD durations were made.
The hazard function can be used to provide insight in the way mechanisms underlying brain state switches work. In this experiment, the stopping of an SWD, which is a switch from the seizure state to normal state, was examined. This was done by calculating the hazard function of the SWD durations. An increase of the hazard function means that the probability of an SWD being terminated (given that it has not stopped yet) is increased. Conversely, a decrease of the hazard function means that the probability of SWD termination is also decreased. A constant hazard function means that the probability of SWD termination does not change during the seizure; it does not matter whether an SWD has been ongoing for a long time or has just started. For more info on the used algorithms, see Maris et al. [42] . All SWD durations of a single rat were run through the hazard function script [42] in MATLAB R2018B (The MathWorks, Inc., Massachusetts, U.S.A.). In order to allow averaging over groups, bin lengths, based on SWD duration (in seconds), were defined on a logarithmic scale.
Physical activity (PIR)
The WIN-treated animals and controls were compared regarding their total amount of bodily movements as recorded with the PIR motion sensors. The amount of movement during 24 h was expressed as a percentage of time.
Frequency spectrum
Ten 2-min, randomly selected EEG segments, devoid of SWDs or otherwise epileptiform activity for each of the animals, were used for the analyses of the background EEG. Each segment was subsequently divided into twelve segments of 10 s each, which were assigned to either an 'active' or a 'passive' state subset, based on visual inspection of the PIR.
Subsequently, spectral information was calculated using the fast Fourier transformation analysis in BrainVision Analyzer 2.0 (Brain Products GmbH), using a Hanning window and a resolution of 0.1 Hz. The spectra were then normalized, with the total power between 1 and 100 Hz being 100%.
The peak frequency of the theta band was established after applying a 10-step smoothing in Graphpad Prism 6.0 (GraphPad Software, San Diego, California USA) on the normalized frequency spectra.
Statistical analyses
IBM SPSS 25.0 for Windows (SPSS Inc., Chicago, Illinois USA) and GraphPad Prism 6.0 for Windows (GraphPad Software, San Diego, California USA) were used to perform statistical analyses.
Mean SWD duration, SWD incidence (per hour), and bodily activity (PIR) were compared for each condition by means of a repeated measures' generalized linear model with treatment (WIN, control) as between-subjects factor and time (acute, subchronic) as withinsubjects' factor. Group means and standard error of the means (SEMs) are given. To investigate if baseline recordings were not significantly different between WIN animals and controls, baseline incidence and duration were analyzed by means of t-tests for independent samples.
The hazard rates were analyzed by comparing the time bins (see paragraph on Hazard rate) in separate repeated measures' generalized linear models with treatment (WIN, control) as between-subjects' factor and time (baseline, acute, subchronic) as within-subjects' factor. To control for multiple comparisons' bias, only clusters of at least 3 consecutive significant differences (p ≤ 0.05) were taken into consideration for showing significance.
Repeated measures' generalized linear model analyses were used as well for the EEG frequency spectrum, with treatment (WIN, control) as between-subjects factor and state (active, passive), time (acute, subchronic), and EEG channel (cortex, hippocampus, and thalamus) as within-subjects' factors. Putative differences between baselines were analyzed in a separate generalized linear model analysis with the same states and channels as between-subjects' factors. Theta peak frequencies were analyzed separately for treatment effects by means of a generalized linear models with treatment (WIN, control) as betweensubjects' factor and time (baseline, acute, subchronic) as withinsubjects' factor.
Results
SWD incidence
A representative example of an SWD can be seen in Fig. 1 . Recordings from the frontal cortex showed a very pronounced 'spike' component, which made this channel the most suited for automated SWD detection. All SWD quantifying data are therefore based on this channel. No SWD activity was found in the hippocampus channel. The thalamus channel shows clear SWD activity, but here, the 'spike' component might have a somewhat smaller amplitude in agreement with Sitnikova and van Luijtelaar [48] .
No effects of WIN on SWD incidence were found on the total recording period of 24 h (Fig. 2) ; the number of SWDs per hour remained the same throughout the treatment. No time-treatment interaction was found, F(1, 12) = 0.017, p = 0.90; no time effect was found, F(1, 12) = 0.45, p = 0.52; and no treatment effect was found, F(1, 12) = 0.54, p = 0.48. Baseline values for the two groups were not significantly different, t(12) = 2.1, p = 0.057. Also, when examining the first 3 h after injection separately, no effects of WIN were found either (Appendix A,: Fig. A.1 ).
SWD duration
A significant treatment effect was found, F(1, 12) = 32.10, p = 0.0001. The WIN-treated rats had a significantly longer mean SWD duration than controls in the acute (p = 0.002) and after the subchronic phases of the study (0.016). There were no other differences between the two time points. Baselines were not significantly different, t(12) = 0.002, p = 0.999. In control animals, the mean duration of SWDs (Fig. 3) remained constant throughout the treatment at an average of 8.4-s SEM: 0.25. The WIN-treated rats had a similar SWD duration, of 8.7-s SEM: 0.49, prior to the injections. After that, the duration increased to 11.9-s SEM: 0.64 and 11.5-s SEM: 1.00 after the acute and subchronic injections, respectively. Fig. 4 shows the distribution of SWD durations during baseline recordings ( Fig. 4a ), acute treatment (Fig. 4b) , and subchronic treatment ( Fig. 4c) and their corresponding hazard rates ( Fig. 4d , e, and f, respectively). Hazard rates reach a peak at an SWD length of approximately 10-12 s in the control group. This pattern remains the same throughout the treatment. The hazard rate curves for the WIN-treated animals are overall more flat from the start of the treatment and remain like that after 2 weeks of treatment.
The t-profile on the hazard rate curve on the acute phase of the study showed a range (5.04-20.16 s) of treatment effects. A treatment effect was found for this range, F(1, 25) = 35.9, p b 0.0001. Hazard rates were lower in the WIN-treated group, meaning that the probability that an SWD with a length within that range will stop is lower. No time effect was found, F(1, 25) = 2.0, p = 0.17, nor was there a time-treatment interaction, F(1, 25) = 0.25, p = 0.62. In the baselines, there were no differences, t(13) = 0.31, p = 0.76. An overview of the t-profile can be found in Table A .1 (Appendix A). The treatment affects the stopping probability of SWDs and thereby their duration. This can also be seen in Fig. 4g , which shows the duration of every individual SWD recorded during baseline and during acute treatment; during treatment, there is a larger number of long (≥ 25 s) SWDs in WIN-treated animals, t(13) = 3.39, p = 0.005. During acute treatment, WIN-treated animals had 43.4 SEM, 11.2 SWDs of ≥ 25 s compared with 6.3 SEM, 3.2 for controls. There was no difference in the baselines of each group, t(13) = 0.80, p = 0.44. During baselines, WIN-treated animals had 11.1 SEM, 3.4 SWDs of ≥ 25 s compared with 7.9 SEM, 2.5 for controls.
Physical activity (PIR)
The quantified movement (Fig. 5 ) did not differ between the control (55.1% SEM: 0.11) and WIN-treated rats (54.9% SEM: 0.10). No significant treatment effect was found, F(1, 12) = 0.24, p = 0.63. No time-treatment interaction was found, F(1, 12) = 0.088, p = 0.77. However, a significant time effect was found, F(1, 12) = 18.35, p = 0.001. In both groups, animals were more active in the 24 h following the last of the WIN injections. The two groups did not differ in the baseline, t(13) = 1.07, p = 0.31.
Frequency spectrum
Neither drug nor time or interaction effects were found in spectral content of ongoing EEG (Appendix A, Fig. A.2 ). However, a significant state-brain region interaction effect was found, F(2, 18) = 16.0, p = 0.001. Theta power was higher during active behavior than during Fig. 1 . Representative example of a spike-and-wave discharge (SWD). Recordings from the frontal cortex showed a pronounced 'spike' component. No SWD activity was found in the hippocampus channel. The thalamus channel seems to show some SWD activities, but here, the 'spike' component is far less pronounced. passive behavior but only in the hippocampus and thalamus channels. This effect was present both in WIN-treated and control rats during acute as well as subchronic treatments.
The mean theta peak frequency was in 7.4-Hz SEM: 0.18 for all groups. Neither drug nor time or interaction effects were found in theta peak frequencies of the ongoing EEG (Appendix A, Fig. A.3) . Fig. 3 . Mean SWD duration. All values are group averages with SEMs. During baseline (BL) recordings, the mean SWD duration was around 8.5 s in both groups. Injection with WIN (EXP) resulted in significantly longer SWDs. This was seen after acute as well as after subchronic treatments. ** p = 0.0001; * p = 0.002. 
Discussion
This EEG study, in which WAG/Rij rats were subchronically treated with a cannabinoid agonist at adult age, showed treatment effects on two SWD characteristics. Firstly, the treatment resulted in an increase in mean SWD duration. Secondly, the treatment led to a decreased hazard rate for SWDs with a duration between 5 and 20 s. Both changes in SWD characteristics remained constant throughout the duration of the treatment. Additionally, the spectral content of the ongoing EEG was analyzed as well as the physical activity of the rats. Here, no effects of the treatments were found.
The increase in SWD duration is in line with previous findings [8] ; a single injection of WIN resulted in an increased SWD duration. However, contrary to what has been previously reported, we did not find any effects of WIN on SWD incidence. Systemic injection of CB 1 agonists has been described to reduce SWD incidence in the first 3 h after injection [8, 49] . Also, local injection of WIN in the cortex, the RTN and the ventroposteromedial (VPM) thalamic nucleus, decreases the number of SWDs [50] . This increase lasts approximately 3 h as well. In the present study, EEG was recorded for a longer period, but in the first 3 h, no effects on SWD incidence were found (Fig. A.1) . In a previous study by van Rijn et al. [8] , WIN was injected in several doses, up to 12 mg/kg. Only in rats injected with the highest dose, a decrease in SWD incidence was consistently reported, i.e., in more than one of the experiments performed. Moreover, animals in the highest dose group were reported to exhibit a decrease in motor activity. Since SWD incidence is known to be dependent on the level of vigilance [51, 52] , it is therefore likely that the decrease in activity found in the previous study, rather than the drug itself, caused the decrease in SWD incidence. In the present study, a lower dose was used, and no changes in activity were found. In fact, the only difference in physical activity that was found was an increase in the third week of treatment, both in the treatment and the control group, which is most likely the result of habituation to the procedure of moving the animals from their home cages to the recording cages.
Our second finding, the decreased hazard rates, reveals that the SWD stopping mechanism is affected after exposure to WIN. This is in line with our first finding, the increase in mean SWD duration. However, it shows that acute and subchronic WIN treatments did not enhance overall SWD lengths, but rather, it affected the distribution of SWD durations. A lower hazard rate in the 5-20-s range of seizure durations implies that once an SWD reaches a duration of 5 s, it is less likely to be terminated in WIN-treated rats than in controls, resulting in a relatively small number of very long SWDs as can be seen in Fig. 4 .
A CB 1 -mediated inhibition of gamma-aminobutyric acid (GABA) release seems to be the most likely explanation as changes in GABAergic neurotransmission with vigabatrin, a drug that increases GABA concentrations by irreversibly inhibiting GABA transaminase [53] , is known to affect the SWD stopping mechanism as well [42, 54, 55] . In rats treated with vigabatrin, the likelihood of observing both very short and very long SWDs is higher in vigabatrin-treated animals than in controls [42] . This results in, among other things, very short SWDs, which seem to be the direct result of enhanced levels of GABA. Indeed, similarly short SWDs have been observed in rats treated with GABA agonists diazepam [56] and loreclezole [57, 58] .
It has been proposed that corticothalamocortical as well as intrathalamic processes play a role in SWD termination. More specifically, both corticothalamic and the intrathalamic coupling changes are associated with SWD termination and include the rostral part of the RTN [59, 60] . CB 1 receptors are known to be abundantly present in the RTN [8, 61] . It is therefore likely that activation of CB 1 receptors with WIN leads to an inhibition in GABA release in their synapses. In this light, it might be relevant to mention that WAG/Rij rats have a deficient GABAergic system [62, 63] . More specifically, WAG/Rij rats have a specific loss of alpha3 subunit immunoreactivity at inhibitory, GABAergic synapses in the RTN [64] . It is therefore speculated that the decreased GABAergic function of the RTN in dampening 7-11-Hz oscillations, including SWDs, is further reinforced by the administration of the CB1 agonist. All of the effects described above remained constant after repeated administration. This suggests that no tolerance has occurred. The absence of tolerance is quite remarkable since it is generally assumed that CB 1 receptors are prone to plasticity [13, 16, 36, 40] . However, it has been previously reported that repeated administration of WIN55,212-2 does not lead to behavioral tolerance despite producing acute and sustained motor-suppressant effects [41] . Whereas chronic treatment with WIN results in slight CB 1 receptor desensitization in mice, it was much lower than when treated with Δ 9 -THC [65, 66] . Similarly, evidence from rats with pentylenetetrazole (PTZ)-induced tonic-clonic seizures shows that chronic exposure to cannabinoids did not affect seizure susceptibility [67] . Therefore, the development of tolerance to CB 1 agonists seems to be dependent on several factors, including the used compound, experimental protocol, and dose [41, 68] .
A clear peak in theta activity was observed in the frequency spectrum of the ongoing EEG of both treatment groups when behaviorally active. Theta rhythm is associated with locomotor activity [69] . The PIR signals we measured allow only to distinguish between active and passive states. There were neither drug-induced differences in the quantity of active and passive behaviors nor effects on For WIN-treated animals as well as for controls, the average quantified movement during recording was between 54.9 and 55.2% of the maximum deflection, before (BL) and throughout the treatment period (EXP: acute, subchronic). No treatment effect was found. However, both controls and WIN-treated animals were found to be significantly more active after the subchronic phase of the treatment. Over the entire recording period, no differences in SWD incidence were found (Results, Fig. 1 ). However, since it was previously reported that SWD incidence decreased in the first 3 h after injection with WIN [8] , the average SWD incidence in the first 3-h postinjection (slopes of the cumulative incidence) was compared with baselines. Neither a time-treatment interaction was found, F(1, 12) = 0.88, p = 0.37, nor a main effect of treatment, F(1, 12) = 0.001, p = 0.97, was found. the frequency spectra. Some CB 1 agonists do affect the EEG frequency spectrum in animals [24, 70] and humans [38, 62] . All the aforementioned studies used either Δ 9 -THC or CP-55940, a cannabinoid that mimics Δ 9 -THC [71] . Although all these compounds, like WIN, are CB 1 agonists, differences in their molecular structure may explain the differences in their effects on the EEG spectrum. In summary, acute and subchronic administration with the cannabinoid agonist WIN in adult WAG/Rij rats resulted in a long lasting increase of long SWDs, which is most likely a direct result of CB 1 receptor agonism and a subsequent decrease in the availability of GABA in the RTN. We did not find any evidence for the development of tolerance to this agonist nor did with we find any effects on the frequency spectrum of the ongoing EEG.
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